QGEN
Qiagen N.V. NYSE Listed Jun 28, 1996$33.52
Mkt Cap $6.9B
52w Low $33.17
1.4% of range
52w High $57.82
50d MA $40.80
200d MA $46.02
P/E (TTM)
16.8x
EV/EBITDA
14.9x
P/B
1.9x
Debt/Equity
0.4x
ROE
11.2%
P/FCF
21.7x
RSI (14)
—
ATR (14)
—
Beta
0.79
50d MA
$40.80
200d MA
$46.02
Avg Volume
2.0M
QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories. It also provides interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; assays for prenatal testing and detection of sexually transmitted diseases and HPV, as well as assays for analysis of genomic variants, such as mutations, insertions, deletions, and fusions; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. In addition, it offers PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping, and gene regulation instruments and technologies; human ID and forensics assay consumables, including STR assays for human ID, and assays for food contamination; PCR instruments consist of digital PCR solutions; and developed and configured OEM consumables. Further, the company provides predefined and custom NGS gene panels, library prep kits and components, and whole genome amplification; QIAGEN consumables and instruments, as well as bioinformatics solutions; and custom laboratory and genomic services. It serves molecular diagnostics, academia, pharmaceutical, and applied testing customers. It has a strategic alliance agreement with Sysmex Corporation and OncXerna Therapeutics, as well as an agreement with Mirati. The company was founded in 1986 and is headquartered in Venlo, the Netherlands.
Hulsterweg 82 · Venlo 5912 PL · NL
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 6, 2026 | AMC | 0.55 | 0.54 | -1.8% | 34.44 | -2.3% | -2.7% | — | — | — | — | — |
| Feb 4, 2026 | AMC | 0.61 | 0.62 | +1.6% | 51.71 | -3.5% | -0.9% | -0.5% | -0.3% | +0.6% | -0.0% | — |
| Nov 4, 2025 | AMC | 0.61 | 0.64 | +4.9% | 44.16 | -1.7% | -0.2% | -2.2% | +1.2% | -0.9% | +2.4% | — |
| Aug 5, 2025 | AMC | 0.60 | 0.60 | +0.0% | 49.95 | -0.4% | -4.9% | +1.8% | -0.7% | -0.1% | +2.0% | — |
| May 7, 2025 | AMC | 0.50 | 0.55 | +9.3% | 42.63 | -0.1% | -1.1% | -0.7% | +2.6% | -2.0% | -2.3% | — |
| Feb 5, 2025 | AMC | 0.60 | 0.61 | +1.7% | 43.80 | -3.9% | -3.1% | -2.6% | -3.0% | -2.0% | +2.2% | — |
| Nov 6, 2024 | AMC | 0.54 | 0.57 | +5.6% | 42.86 | +3.0% | +0.7% | -0.9% | +0.7% | -1.8% | -1.4% | — |
| Jul 31, 2024 | AMC | 0.53 | 0.57 | +7.5% | 43.47 | +0.6% | +2.9% | +1.1% | -3.0% | -0.4% | -0.6% | — |
| Apr 29, 2024 | AMC | 0.44 | 0.46 | +4.5% | 41.33 | -1.9% | +0.1% | +1.1% | -0.3% | +0.7% | -0.9% | — |
| Feb 6, 2024 | AMC | 0.55 | 0.55 | +0.0% | 43.78 | -1.3% | -2.9% | +1.4% | +0.8% | -1.5% | -2.2% | — |
| Oct 30, 2023 | AMC | 0.52 | 0.53 | +1.9% | 35.82 | +2.5% | +5.3% | +1.2% | +0.9% | +2.6% | -0.7% | — |
| Aug 8, 2023 | AMC | 0.53 | 0.54 | +1.9% | 44.93 | +2.7% | +0.3% | -0.9% | -1.4% | +0.8% | -0.6% | — |
| May 3, 2023 | AMC | 0.50 | 0.54 | +8.0% | 45.27 | +3.4% | +2.5% | -0.1% | +0.2% | -2.2% | +1.1% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 29 | Baird | Upgrade | Neutral → Outperform | $43 | $34.02 | $33.62 | -1.2% | -1.2% | +2.9% | -1.0% | -0.8% | +0.1% |
| Apr 14 | Barclays | Downgrade | Overweight → Equal Weight | — | $41.91 | $41.89 | -0.0% | -0.4% | -0.3% | -1.6% | +0.7% | -0.5% |
| Mar 13 | Deutsche Bank | Upgrade | Hold → Buy | — | $41.12 | $41.83 | +1.7% | -1.3% | +0.8% | +1.5% | -2.6% | +0.5% |
| Feb 6 | Stifel | Maintains | Hold → Hold | — | $51.23 | $51.25 | +0.0% | -0.5% | -0.3% | +0.6% | -0.0% | -0.4% |
| Feb 6 | JP Morgan | Maintains | Overweight → Overweight | — | $51.23 | $51.25 | +0.0% | -0.5% | -0.3% | +0.6% | -0.0% | -0.4% |
| Feb 6 | Citigroup | Maintains | Neutral → Neutral | — | $51.23 | $51.25 | +0.0% | -0.5% | -0.3% | +0.6% | -0.0% | -0.4% |
| Jan 22 | Deutsche Bank | Downgrade | Buy → Hold | — | $55.66 | $54.72 | -1.7% | -2.5% | +2.5% | -2.5% | +0.0% | -0.4% |
| Dec 15 | Barclays | Maintains | Overweight → Overweight | — | $45.22 | $47.92 | +6.0% | +5.8% | -0.9% | +0.4% | -0.5% | +1.4% |
| Dec 11 | Citigroup | Downgrade | Buy → Neutral | — | $45.66 | $45.59 | -0.2% | -0.5% | -0.5% | +5.8% | -0.9% | +0.4% |
| Oct 2 | Barclays | Maintains | Overweight → Overweight | — | $46.32 | $46.30 | -0.0% | -0.2% | +1.2% | +0.3% | -0.3% | +2.1% |
| Aug 7 | UBS | Maintains | Neutral → Neutral | — | $47.49 | $47.93 | +0.9% | +1.8% | -0.7% | -0.1% | +2.0% | +0.5% |
| Jun 26 | BofA Securities | Maintains | Buy → Buy | — | $47.45 | $48.30 | +1.8% | +1.2% | -0.6% | +0.6% | +0.3% | +0.9% |
| Apr 21 | Baird | Maintains | Neutral → Neutral | — | $40.71 | $40.61 | -0.2% | -0.6% | +4.6% | -0.0% | +1.7% | -2.3% |
| Apr 4 | Redburn Atlantic | Downgrade | Buy → Neutral | — | $40.37 | $39.61 | -1.9% | -5.2% | +5.4% | -3.7% | +6.8% | -3.3% |
| Feb 19 | Baird | Downgrade | Outperform → Neutral | — | $40.01 | $39.36 | -1.6% | -2.0% | -1.7% | +2.6% | +0.9% | -0.5% |
| Feb 7 | UBS | Maintains | Neutral → Neutral | — | $42.44 | $41.38 | -2.5% | -2.6% | -3.0% | -2.0% | +2.2% | -0.2% |
| Jan 6 | Morgan Stanley | Downgrade | Overweight → Equal Weight | — | $43.94 | $43.55 | -0.9% | -0.4% | +0.3% | +0.7% | -1.3% | +2.9% |
| Dec 10 | Jefferies | Upgrade | Hold → Buy | — | $43.31 | $45.10 | +4.1% | +3.9% | +0.2% | -0.4% | -1.2% | -0.0% |
| Feb 8 | JP Morgan | Maintains | Overweight → Overweight | — | $42.52 | $42.74 | +0.5% | +1.4% | +0.8% | -1.5% | -2.2% | +0.0% |
| Feb 8 | Citigroup | Maintains | Buy → Buy | — | $42.52 | $42.74 | +0.5% | +1.4% | +0.8% | -1.5% | -2.2% | +0.0% |
| Dec 20 | JP Morgan | Maintains | Overweight → Overweight | — | $43.28 | $43.20 | -0.2% | -2.2% | +2.6% | +0.2% | +0.6% | +0.0% |
| Dec 7 | Goldman Sachs | Upgrade | Neutral → Buy | — | $41.74 | $42.20 | +1.1% | +1.4% | -0.6% | +0.7% | -0.4% | +2.8% |
| Nov 2 | UBS | Maintains | Neutral → Neutral | — | $38.15 | $38.45 | +0.8% | +0.9% | +2.6% | -0.7% | +0.7% | -1.2% |
| Oct 16 | JP Morgan | Maintains | Overweight → Overweight | — | $38.74 | $38.82 | +0.2% | +1.8% | -0.6% | -2.8% | -0.8% | +0.0% |
| Sep 25 | Citigroup | Maintains | Buy → Buy | — | $39.71 | $39.39 | -0.8% | -0.7% | +1.2% | -0.4% | +0.6% | +2.0% |
| Aug 8 | UBS | Maintains | Neutral → Neutral | — | $45.55 | $45.39 | -0.4% | -1.4% | +0.3% | -0.9% | -1.4% | +0.8% |
| Feb 8 | UBS | Maintains | Neutral → Neutral | — | $50.17 | $51.02 | +1.7% | -0.9% | -0.4% | +0.1% | -0.7% | -0.2% |
| Feb 8 | Citigroup | Maintains | Buy → Buy | — | $50.17 | $51.02 | +1.7% | -0.9% | -0.4% | +0.1% | -0.7% | -0.2% |
| Nov 8 | Citigroup | Maintains | Buy → Buy | — | $42.24 | $43.97 | +4.1% | +5.6% | +0.5% | +4.9% | +3.1% | -2.1% |
| Dec 13 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $54.75 | $54.76 | +0.0% | +0.8% | -1.2% | +3.3% | -1.0% | -0.6% |
| Oct 14 | Redburn Partners | Maintains | Buy → Buy | — | $51.68 | $52.26 | +1.1% | +1.0% | -0.3% | +0.9% | +0.9% | +1.2% |
| Jul 13 | Kepler Cheuvreux | Downgrade | Buy → Hold | — | $49.15 | $47.48 | -3.4% | -3.4% | -1.3% | +2.9% | -1.3% | +2.9% |
| Jun 3 | Goldman Sachs | Maintains | Neutral → Neutral | — | $47.40 | $46.77 | -1.3% | -0.9% | -0.1% | +1.3% | -0.3% | -0.2% |
| Oct 5 | BofA Securities | Upgrade | Neutral → Buy | — | $52.71 | $53.06 | +0.7% | +1.7% | +2.0% | +0.2% | -0.6% | +1.3% |
| Sep 27 | Kepler Cheuvreux | Upgrade | Hold → Buy | — | — | — | — | — | — | — | — | — |
| Aug 25 | Commerzbank | Upgrade | Hold → Buy | — | $52.00 | $51.53 | -0.9% | +0.3% | +0.5% | -3.4% | +0.7% | +0.6% |
| Aug 23 | Citigroup | Upgrade | Neutral → Buy | — | — | — | — | — | — | — | — | — |
| Aug 20 | JP Morgan | Maintains | Overweight → Overweight | — | $52.81 | $52.44 | -0.7% | -2.2% | +2.1% | -1.4% | +0.3% | +0.5% |
| Aug 13 | Deutsche Bank | Upgrade | Hold → Buy | — | $48.77 | $49.37 | +1.2% | +0.5% | +1.7% | +3.8% | +1.7% | +0.4% |
| Aug 13 | Exane BNP Paribas | Upgrade | Neutral → Outperform | — | $48.77 | $49.37 | +1.2% | +0.5% | +1.7% | +3.8% | +1.7% | +0.4% |
| Apr 1 | Stifel | Maintains | Hold → Hold | — | $41.90 | $40.59 | -3.1% | -3.3% | -0.3% | +0.4% | -0.7% | +0.5% |
| Mar 5 | CFRA | Maintains | Hold → Hold | — | $41.80 | $41.94 | +0.3% | +0.1% | +0.1% | -0.6% | +0.2% | -0.8% |
| Feb 5 | CFRA | Maintains | Hold → Hold | — | $33.41 | $36.22 | +8.4% | +5.1% | +2.5% | -0.7% | +0.8% | +0.6% |
| Jan 9 | UBS | Maintains | Neutral → Neutral | — | $33.92 | $34.22 | +0.9% | +2.9% | -0.2% | +1.5% | +0.7% | -3.9% |
| Jan 8 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $33.53 | $33.44 | -0.3% | +1.2% | +2.9% | -0.2% | +1.5% | +0.7% |
| Jan 7 | Citigroup | Maintains | Neutral → Neutral | — | $33.73 | $33.49 | -0.7% | -0.6% | +1.2% | +2.9% | -0.2% | +1.6% |
| Nov 17 | Commerzbank | Upgrade | Hold → Buy | — | — | — | — | — | — | — | — | — |
| Nov 15 | Stifel Nicolaus | Maintains | Hold → Hold | — | $37.55 | $37.96 | +1.1% | +8.8% | +1.2% | -0.0% | -0.7% | +0.6% |
| Nov 13 | JP Morgan | Upgrade | Underweight → Overweight | — | $32.50 | $32.50 | +0.0% | +9.9% | +5.2% | +8.8% | +1.2% | -0.0% |
| Oct 8 | Bank of America | Maintains | Neutral → Neutral | — | $32.30 | $26.22 | -18.8% | -20.8% | +3.7% | +3.4% | -0.6% | +0.6% |
No insider trades available.
Data updated apr 26, 2026 9:30pm
· Source: massive.com